EN
VN
Hanvet participated in the forum Applications of New Advances in Veterinary Vaccine Technology in Vietnam
On the morning of December 28, Hanvet participated in the online forum titled "Applications of New Advances in Veterinary Vaccine Technology in Vietnam," held in Hanoi. During the forum, Hanvet presented its advanced technology for producing the Rabiva - a rabies vaccine for cats and dogs from Hanvet. This technology, which meets international standards, aligns with Vietnam's National Rabies Control Program.
.jpeg)
Discussion about Rabiva Development Process
To tackle rabies effectively, Hanvet uses Vero cells from the American ATCC CCL81 cell bank and the PM strain of rabies virus transferred from the U.S. Centers for Disease Control and Prevention (CDC). The company also applies advanced antigen purification technologies to enhance the vaccine's protective efficacy.
.jpeg)
Hanvet representatives detailed the meticulous production process, including cell culture, virus harvesting, purification, and stringent quality control based on eight strict criteria.
.jpeg)
Proven Effectiveness and Global Reach
Rabiva has been widely adopted across Vietnam and has successfully entered international markets such as Myanmar, Sri Lanka, the UAE, and several African nations.
“At the local level, Rabiva has proven its effectiveness in rabies prevention, supporting Vietnam's efforts in controlling the disease and safeguarding public health. With these contributions, Hanvet plays a vital role in the National Rabies Control Program, aiming to enhance the safety of livestock and the community,” said Mr. Nguyen Thanh Ba, Director of the Vaccine and Biological Research Center at Pharmaceutical and Veterinary Material J.S.C Hanvet.
Discussion about Rabiva Development Process
To tackle rabies effectively, Hanvet uses Vero cells from the American ATCC CCL81 cell bank and the PM strain of rabies virus transferred from the U.S. Centers for Disease Control and Prevention (CDC). The company also applies advanced antigen purification technologies to enhance the vaccine's protective efficacy.
Hanvet representatives detailed the meticulous production process, including cell culture, virus harvesting, purification, and stringent quality control based on eight strict criteria.
Proven Effectiveness and Global Reach
Rabiva has been widely adopted across Vietnam and has successfully entered international markets such as Myanmar, Sri Lanka, the UAE, and several African nations.
“At the local level, Rabiva has proven its effectiveness in rabies prevention, supporting Vietnam's efforts in controlling the disease and safeguarding public health. With these contributions, Hanvet plays a vital role in the National Rabies Control Program, aiming to enhance the safety of livestock and the community,” said Mr. Nguyen Thanh Ba, Director of the Vaccine and Biological Research Center at Pharmaceutical and Veterinary Material J.S.C Hanvet.
Thông tin khác
.jpg)
